VINORELBINE PIERRE FABRE vinorelbine 50mg/5mL (as tartrate) injection vial

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

vinorelbine tartrate, Quantity: 13.85 mg/mL (Equivalent: vinorelbine, Qty 10 mg/mL)

Verfügbar ab:

Pierre Fabre Australia Pty Ltd

Darreichungsform:

Injection, concentrated

Zusammensetzung:

Excipient Ingredients: water for injections

Verabreichungsweg:

Intravenous

Einheiten im Paket:

1 x 5mL, 10 x 5mL

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

Vinorelbine Pierre Fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. Vinorelbine Pierre Fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage IB or greater.

Produktbesonderheiten:

Visual Identification: A clear, colourless to pale yellow solution; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Berechtigungsstatus:

Licence status A

Berechtigungsdatum:

2000-08-04